Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 48.e9-48.e17

  Sapre, Nikhil ^a,b   Anderson, Paul D ^a,b   Costello, Anthony J ^a,b   Hovens, Christopher M ^a,b   Corcoran, Niall M ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bladder cancer; MicroRNA; Molecular biomarkers; Recurrence; Urinary biomarker

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; BLADDER TUMOR ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYALURONIC ACID; HYALURONIDASE; MESSENGER RNA; MICRORNA; NUCLEAR MATRIX PROTEIN 22; SIALYL LEWIS X ANTIGEN; SURVIVIN; TELOMERASE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; COPY NUMBER VARIATION; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC RISK; GENETIC SCREENING; HEALTH CARE COST; HETEROZYGOSITY LOSS; HIGH RESOLUTION MELTING ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LABORATORY DEVICE; MEDICAL LITERATURE; MEDLINE; METHYLATION SPECIFIC HIGH RESOLUTION MELTING ANALYSIS; METHYLATION SPECIFIC MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NON INVASIVE MEASUREMENT; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; PUBLICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; URINALYSIS; URINE CYTOLOGY;

BLADDER CANCER; MICRORNA; MOLECULAR BIOMARKERS; RECURRENCE; URINARY BIOMARKER;

CYSTOSCOPY; DNA METHYLATION; HUMANS; MICRORNAS; MICROSATELLITE REPEATS; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84890795535     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.07.002     Document Type: Review

References (65)

1. Schrag D., Hsieh L.J., Rabbani F., Bach P.B., Herr H., Begg C.B. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003, 95(8):588-597.
2. Avritscher E.B., Cooksley C.D., Grossman H.B., Sabichi A.L., Hamblin L., Dinney C.P., et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006, 68(3):549-553.
3. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93(14):1054-1061.
4. Mowatt G., Zhu S., Kilonzo M., Boachie C., Fraser C., Griffiths T.R., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14(4):1-331. (iii-iv).
5. Sokolova I.A., Halling K.C., Jenkins R.B., Burkhardt H.M., Meyer R.G., Seelig S.A., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000, 2(3):116-123.
6. Villicana P., Whiting B., Goodison S., Rosser C.J. Urine-based assays for the detection of bladder cancer. Biomark Med 2009, 3(3):265.
7. Friedrich M.G., Toma M.I., Hellstern A., Pantel K., Weisenberger D.J., Noldus J., et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003, 92(9):911-914.
8. Sarosdy M.F., Schellhammer P., Bokinsky G., Kahn P., Chao R., Yore L., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002, 168(5):1950-1954.
9. Bollmann M., Heller H., Bankfalvi A., Griefingholt H., Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?. BJU Int 2005, 95(9):1219-1225.
10. Kipp B.R., Karnes R.J., Brankley S.M., Harwood A.R., Pankratz V.S., Sebo T.J., et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005, 173(2):401-404.
11. Park H.S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S., et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008, 100(19):1401-1411.
12. Ellegren H. Microsatellites: simple sequences with complex evolution. Nat Rev Genet 2004, 5(6):435-445.
13. Seripa D., Parrella P., Gallucci M., Gravina C., Papa S., Fortunato P., et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 2001, 95(6):364-369.
14. Frigerio S., Padberg B.C., Strebel R.T., Lenggenhager D.M., Messthaler A., Abdou M.T., et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 2007, 121(2):329-338.
15. Hoque M.O., Lee J., Begum S., Yamashita K., Engles J.M., Schoenberg M., et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res 2003, 63(18):5723-5726.
16. de Bekker-Grob E.W., van der Aa M.N., Zwarthoff E.C., Eijkemans M.J., van Rhijn B.W., van der Kwast T.H., et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. BJU Int 2009, 104(1):41-47.
17. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., Boogaard M.W., Nijsen Y., van der Keur K.A., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol 2009, 55(3):659-667.
18. Coenen M.J., Ploeg M., Schijvenaars M.M., Cornel E.B., Karthaus H.F., Scheffer H., et al. Allelic imbalance analysis using a single-nucleotide polymorphism microarray for the detection of bladder cancer recurrence. Clin Cancer Res 2008, 14(24):8198-8204.
19. Wild P.J., Fuchs T., Stoehr R., Zimmermann D., Frigerio S., Padberg B., et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1798-1806.
20. Steiner G., Schoenberg M.P., Linn J.F., Mao L., Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997, 3(6):621-624.
21. Roupret M., Hupertan V., Yates D.R., Comperat E., Catto J.W., Meuth M., et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008, 101(11):1448-1453.
22. Jones P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13(7):484-492.
23. Wolff E.M., Chihara Y., Pan F., Weisenberger D.J., Siegmund K.D., Sugano K., et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010, 70(20):8169-8178.
24. Sanchez-Carbayo M. Urine epigenomics: a promising path for bladder cancer diagnostics. Expert Rev Mol Diagn 2012, 12(5):429-432.
25. Chan M.W., Chan L.W., Tang N.L., Tong J.H., Lo K.W., Lee T.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002, 8(2):464-470.
26. Chan M.W., Chan L.W., Tang N.L., Lo K.W., Tong J.H., Chan A.W., et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003, 104(5):611-616.
27. Friedrich M.G., Weisenberger D.J., Cheng J.C., Chandrasoma S., Siegmund K.D., Gonzalgo M.L., et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004, 10(22):7457-7465.
28. Sathyanarayana U.G., Maruyama R., Padar A., Suzuki M., Bondaruk J., Sagalowsky A., et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 2004, 64(4):1425-1430.
29. Dulaimi E., Uzzo R.G., Greenberg R.E., Al-Saleem T., Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004, 10(6):1887-1893.
30. Pu R.T., Laitala L.E., Clark D.P. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol 2006, 50(5):499-506.
31. Hoque M.O., Begum S., Topaloglu O., Chatterjee A., Rosenbaum E., Van Criekinge W., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006, 98(14):996-1004.
32. Urakami S., Shiina H., Enokida H., Kawakami T., Kawamoto K., Hirata H., et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006, 12(7 Pt 1):2109-2116.
33. Yates D.R., Rehman I., Meuth M., Cross S.S., Hamdy F.C., Catto J.W. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006, 25(13):1984-1988.
34. Yu J., Zhu T., Wang Z., Zhang H., Qian Z., Xu H., et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007, 13(24):7296-7304.
35. Cebrian V., Alvarez M., Aleman A., Palou J., Bellmunt J., Gonzalez-Peramato P., et al. Discovery of myopodin methylation in bladder cancer. J Pathol 2008, 216(1):111-119.
36. Costa V.L., Henrique R., Danielsen S.A., Duarte-Pereira S., Eknaes M., Skotheim R.I., et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010, 16(23):5842-5851.
37. Lin H.H., Ke H.L., Huang S.P., Wu W.J., Chen Y.K., Chang L.L. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 2010, 28(6):597-602.
38. Renard I., Joniau S., van Cleynenbreugel B., Collette C., Naome C., Vlassenbroeck I., et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010, 58(1):96-104.
39. Chung W., Bondaruk J., Jelinek J., Lotan Y., Liang S., Czerniak B., et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 2011, 20(7):1483-1491.
40. Cabello M.J., Grau L., Franco N., Orenes E., Alvarez M., Blanca A., et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn 2011, 13(1):29-40.
41. Serizawa R.R., Ralfkiaer U., Steven K., Lam G.W., Schmiedel S., Schuz J., et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 2011, 129(1):78-87.
42. Vinci S., Giannarini G., Selli C., Kuncova J., Villari D., Valent F., et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol 2011, 29(2):150-156.
43. Chen P.C., Tsai M.H., Yip S.K., Jou Y.C., Ng C.F., Chen Y., et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 2011, 4:45.
44. Zuiverloon T.C., Beukers W., van der Keur K.A., Munoz J.R., Bangma C.H., Lingsma H.F., et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int 2012, 109(6):941-948.
45. Zhao Y., Guo S., Sun J., Huang Z., Zhu T., Zhang H., et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 2012, 7(4):e35175.
46. Reinert T., Borre M., Christiansen A., Hermann G.G., Orntoft T.F., Dyrskjot L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One 2012, 7(10):e46297.
47. Eissa S., Zohny S.F., Shehata H.H., Hegazy M.G., Salem A.M., Esmat M. Urinary retinoic acid receptor-beta2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clin Biochem 2012, 45(6):402-407.
48. Berrada N., Amzazi S., Ameziane El Hassani R., Benbacer L., El Mzibri M., Khyatti M., et al. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARbeta) and survivin genes in tumor tissues and voided urine of bladder cancer patients. Cell Mol Biol (Noisy-le-grand) 2012, OL1744-OL1751. (Suppl. 58).
49. Holyoake A., O'Sullivan P., Pollock R., Best T., Watanabe J., Kajita Y., et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008, 14(3):742-749.
50. O'Sullivan P., Sharples K., Dalphin M., Davidson P., Gilling P., Cambridge L., et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012, 188(3):741-747.
51. Urquidi V., Goodison S., Cai Y., Sun Y., Rosser C.J. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012, 21(12):2149-2158.
52. Bongiovanni L., Pirozzi F., Guidi F., Orsini M., Chiurazzi P., Bassi P.F., et al. Bradeion (SEPT4) as a urinary marker of transitional cell bladder cancer: a real-time polymerase chain reaction study of gene expression. J Urol 2012, 187(6):2223-2227.
53. Wang X.S., Zhang Z., Wang H.C., Cai J.L., Xu Q.W., Li M.Q., et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006, 12(16):4851-4858.
54. van Oers J.M., Lurkin I., van Exsel A.J., Nijsen Y., van Rhijn B.W., van der Aa M.N., et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005, 11(21):7743-7748.
55. Zuiverloon T.C., van der Aa M.N., van der Kwast T.H., Steyerberg E.W., Lingsma H.F., Bangma C.H., et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010, 16(11):3011-3018.
56. Dalbagni G., Han W., Zhang Z.F., Cordon-Cardo C., Saigo P., Fair W.R., et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997, 3(9):1593-1598.
57. Melissourgos N., Kastrinakis N.G., Davilas I., Foukas P., Farmakis A., Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003, 62(2):362-367.
58. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
59. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010, 28(6):655-661.
60. Puerta-Gil P., Garcia-Baquero R., Jia A.Y., Ocana S., Alvarez-Mugica M., Alvarez-Ossorio J.L., et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012, 180(5):1808-1815.
61. Yamada Y., Enokida H., Kojima S., Kawakami K., Chiyomaru T., Tatarano S., et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011, 102(3):522-529.
62. Wang G., Chan E.S., Kwan B.C., Li P.K., Yip S.K., Szeto C.C., et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 2012, 10(2):106-113.
63. Yun S.J., Jeong P., Kim W.T., Kim T.H., Lee Y.S., Song P.H., et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012, 41(5):1871-1878.
64. Miah S., Dudziec E., Drayton R.M., Zlotta A.R., Morgan S.L., Rosario D.J., et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012, 107(1):123-128.
65. Ichimi T., Enokida H., Okuno Y., Kunimoto R., Chiyomaru T., Kawamoto K., et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009, 125(2):345-352.